Cardiogeni

Cardiogeni is a clinical-stage biotechnology group developing regenerative cell medicines for cardiovascular disease.

Its lead programme, CLXR-001, uses engineered immunomodulatory progenitor cells intended to support repair of damaged heart tissue in patients with heart failure. The group is progressing plans for clinical evaluation, including a Phase 2b study, through commercial partnerships. Formerly trading as Celixir, it retains interests in the Cell Therapy Limited operating business following a 2026 ownership transaction.